TCS 1102 is an effective antagonist of the dual orexin receptor. Research indicates that TCS 1102 blocks the ADL-orexin B-mediated locomotion. TCS-1102 (10 and 20 mg/kg, i.p.) were found to decrease fear and anxiety in rats 14 days after exposure to footshock. Furthermore, TCS-1102 (10 mg/kg, i.p.) was found to have anxiolytic effects that were specific for HR when tested in the elevated T-maze.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||100 mM in DMSO
100 mM in Ethanol
Orexins (hypocretins) contribute to fear and avoidance in rats exposed to a single episode of footshocks.
Chen X, et al. Brain Struct Funct. 2014 Nov;219(6):2103-18. PMID: 23955372.
|Related OX Receptor Products|
SB-334867 is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2.
MK-3697 is an isonicotinamide small molecule, acting as a potent and selective Orexin 2 receptor antagonist with Ki = 0.95 nM.
SB408124 (Tocris-1963) is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor.
Suvorexant (MK-4305) is a potent, selective and orally bioavailable antagonist of OX(1)R and OX(2)R for the treatment of insomnia.
MK-6096 is an orally bioavailable potent and selective reversible antagonist of OX(1)R and OX(2)R.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.